Form 4: 89bio Director Charles McWherter Acquires Stock Options

Director Charles McWherter acquired options to purchase 67,700 shares of 89bio, Inc. common stock on August 5, 2024.

Summary

• Charles McWherter, a director of 89bio, Inc., filed a Form 4 on August 7, 2024, reporting a transaction.
• On August 5, 2024, McWherter acquired options to purchase 67,700 shares of 89bio's common stock at an exercise price of $8.39 per share.
• The options vest in equal installments on July 30, 2025, July 30, 2026 and July 30, 2027, contingent upon McWherter's continued service to the company.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a routine event, but it does signal confidence from the director in the company's future.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The vesting schedule indicates a multi-year commitment from the director, aligning his interests with the long-term success of the company.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value.

Comparison to Industry Standards

• Stock option grants are a typical component of compensation packages for directors in publicly traded biotech companies.
• The vesting schedule of the options is fairly standard, with annual vesting over a three-year period being a common practice.
• Comparing the size of the grant to similar companies would require further analysis of 89bio's compensation policies and market capitalization.

Stakeholder Impact

• The stock option grant could have a slightly positive impact on shareholder sentiment, as it aligns the director's interests with those of the shareholders.

Key Dates